Tirzepatide (GIP/GLP-1) Compounded sublingual tirzepatide a dual GIP and GLP-1 receptor agonist available as a sublingual formulation when prescribed by a licensed provider for individualized weight management support
Each vial holds a single dose of the drug
doi: 10.3389/fnut.2024.1433390 Received 15 May 2024 Accepted 30 September 2024 Published 30 October 2024 Volume 11 - 2024 Edited by Anna Maria Aloisi, University of Siena, Italy Reviewed by Vahidreza Ostadmohammadi, Kashan University of Medical Sciences, Iran Anna Petroni, University of Siena, Italy Thomas Herdegen, University of Kiel, Germany Updates Copyright 2024 Hajhashemy, Golpour-Hamedani, Eshaghian, Sadeghi, Khorvash and Askari
Its also approved to reduce cardiovascular risk in adults with heart disease and either obesity or overweight
But for patients, the situation is far less fortunate